In making the jump to Alphabet, Ashkenazi is joining one of the few companies larger than Lilly by market value, as the drugmaker’s worth has swelled substantially due to the success of its obesity and diabetes medicines.
But Alphabet brings in significantly more revenue and profit than does Lilly. In the first quarter, Alphabet reported net income of $23.7 billion on revenue of more than $80 billion. Lilly reported net income of $2.2 billion on revenue of about $8.8 billion over the same period.
Google and Alphabet are getting a CFO with a record of “long-term investment to fuel innovation and growth” as the companies navigate the rapid evolution of artificial intelligence, CEO Sundar Pichai said. “I look forward to working with Anat as we invest responsibly to support our next wave of growth,” Pichai said in a statement.
For Lilly, Ashkenazi’s departure adds to a fair bit of turnover in the company’s top leadership. Over the past nine months, the drugmaker has announced the retirement of key executives including the head of its diabetes division, its treasurer, its chief ethics and compliance officer and its executive vice president of global quality.
Lilly said it’s conducting an internal and external search for a new CFO. Ashkenazi will continue to serve on the executive committee as well as maintain her role of CFO through July, Lilly said.
Ashkenazi holds a bachelor’s degree in economics and business administration from Hebrew University and earned her MBA from Tel Aviv University. She will be based in the Bay Area.
By Kristin Jensen
Source: biopharmadive.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
